EQUITY | The Company’s Certificate of Incorporation, as amended, authorizes the issuance of two classes of stock to be designated “Common Stock” and “Preferred Stock”. The Preferred Stock may be divided into such number of series and with the rights, preferences, privileges and restrictions as the Board of Directors may determine. On June 9, 2020, the Company amended its Charter to increase the number of shares of the Company’s Common Stock and the number of shares of the Company’s Preferred Stock authorized thereunder from an aggregate of 179 million to 350 million, consisting of 345 million shares of Common Stock and 5 million shares of Preferred Stock. Series A Convertible Preferred Stock The Company had 37,467 shares of Series A Preferred outstanding as of June 30, 2020 and December 31, 2019. At June 30, 2020 and December 31, 2019, the Company had cumulative dividends of approximately $1,874,000 and $0, respectively. There were no conversions of Series A Preferred into Common Stock during the three and six months ended June 30, 2020 and 2019. At June 30, 2020, the unpaid Series A Preferred dividend of approximately $1,874,000 is included as a current liability under the caption “Accrued expense” in the Company’s condensed consolidated balance sheet. In conjunction with the Series A Restructuring, as defined in Note 12 below, in July 2020, approximately $1,847,000 in dividends payable to the Series A Holders and payable for the quarters ended March 31, 2020 and June 30, 2020 was waived in consideration for the issuance of Series A-1 Convertible Preferred Stock (“ Series A-1 Preferred Series B Convertible Preferred Stock The Company had 239,400 shares of Series B Convertible Preferred stock, par value $0.01 per share (“ Series B Preferred Common Stock The following table summarizes Common Stock activity for the six months ended June 30, 2020: Common Stock Shares outstanding at December 31, 2019 113,346,472 Shares issued pursuant to option exchange 688,695 Shares issued to secure financing facility 2,500,000 Shares issued for cash 12,500,000 Shares outstanding at June 30, 2020 129,035,167 In February and March of 2020, the Company sold, and Triton purchased, an aggregate of 10,000,000 shares of the Company’s Common Stock for cash. In February, the Company sold 4,000,000 shares of Common Stock for $0.16 per share resulting in gross proceeds to the Company of $640,000. In March 2020, the Company sold 6,000,000 shares of Common Stock resulting in gross proceeds to the Company of $765,000, or a per share purchase price of $0.13 per share. Aggregate net proceeds from this financing approximated $1,387,000 after recognition of direct offering costs. During May 2020, the Company sold 2,500,000 shares of its Common Stock to Lincoln Park pursuant to the Lincoln Park Purchase Agreement for $0.10 per share resulting in proceeds to the Company of $250,000. Also in May 2020, the Company issued to Lincoln Park 2,500,000 shares of its Common Stock as consideration for entering into the Purchase Agreement. The Company has recorded this issuance as a deferred stock issuance cost in the amount of $400,000. Such deferred stock issuance costs will be recognized as a charge against paid in capital in proportion to securities sold under this Purchase Agreement. During the six months ended June 30, 2020, the Company issued 600,000 shares of its Common Stock pursuant to exchange agreements with certain terminated employees whereby such employees exchanged an aggregate 1,200,000 Common Stock purchase options for 600,000 shares of Common Stock as a component of their severance agreement. Disclosure of any incremental compensation expense and the related accounting is set forth in the Stock-Based Compensation section of this note. During the six months ended June 30, 2020, the Company granted 708,916 restricted stock units (“ RSUs Warrants The following table summarizes warrant activity for the following periods: Warrants Weighted-Average Exercise Price Balance at December 31, 2019 1,733,856 $ 0.14 Granted — — Expired/Canceled (40,000 ) 1.46 Exercised — — Balance at June 30, 2020 1,693,856 $ 0.11 As of June 30, 2020, warrants to purchase 1,693,856 Stock-Based Compensation The Company’s 1999 Stock Award Plan (the “ 1999 Plan On June 9, 2020, pursuant to authorization obtained from the Company’s stockholders, the Company adopted the 2020 Omnibus Stock Incentive Plan (the ” 2020 Plan Code The 2020 Plan supersedes and replaces the 1999 Plan and therefore no new awards will be granted under the 1999 Plan. Any awards outstanding under the 1999 Plan on the date of approval of the 2020 Plan will remain subject to the 1999 Plan. All shares of Common Stock remaining authorized and available for issuance under the 1999 Plan and any shares subject to outstanding awards under the 1999 Plan that subsequently expire, terminate, or are surrendered or forfeited for any reason without issuance of shares will automatically become available for issuance under the 2020 Plan. As of June 30, 2020, 29,401,175 shares are available for issuance under the 2020 Plan. ASC 718 requires the use of a valuation model to calculate the fair value of stock-based awards. The Company has elected to use the Black-Scholes option-pricing model, which incorporates various assumptions including volatility, expected life, and interest rates. The Company is required to make various assumptions in the application of the Black-Scholes option-pricing model. The Company has determined that the best measure of expected volatility is based on the historical weekly volatility of the Company’s Common Stock. Historical volatility factors utilized in the Company’s Black-Scholes computations for the six months ended June 30, 2020 and 2019 ranged from 66% to 57%. The Company has elected to estimate the expected life of an award based upon the SEC approved “simplified method” noted under the provisions of Staff Accounting Bulletin Topic 14. The expected term used by the Company during the six months ended June 30, 2019 was 5.17 years. The difference between the actual historical expected life and the simplified method was immaterial. The interest rate used is the risk-free interest rate and is based upon U.S. Treasury rates appropriate for the expected term. Interest rates used in the Company’s Black-Scholes calculations for the six months ended June 30, 2020 and 2019 averaged 2.58%. Dividend yield is zero as the Company does not expect to declare any dividends on the Company’s common shares in the foreseeable future. In addition to the key assumptions used in the Black-Scholes model, the estimated forfeiture rate at the time of valuation is a critical assumption. The Company has adopted the provisions of ASU 2016-09 and will continue to use an estimated annualized forfeiture rate of approximately 0% for corporate officers, 4.1% for members of the Board of Directors and 6.0% for all other employees. A summary of the activity under the Company’s stock option plans is as follows: Options Weighted-Average Exercise Price Balance at December 31, 2019 7,204,672 $ 1.32 Granted 1,750,000 $ 0.15 Expired/Cancelled (7,044,672 ) $ 1.34 Exercised — $ — Balance at June 30, 2020 1,910,000 $ 0.22 During the six months ended June 30, 2020, the Company issued 600,000 shares of its Common Stock pursuant to an exchange agreement with certain terminated employees whereby such employees exchanged 1,200,000 Common Stock purchase options for 600,000 shares of Common Stock as a component of their severance agreement. The Company recorded the grant date fair value of these Common Stock issuances as severance expense in the amount of approximately $86,000. The Company periodically issues RSUs to certain employees which vest over time. When vested, each RSU represents the right to that number of shares of Common Stock equal to the number of RSUs granted. The grant date fair value for RSUs is based upon the market price of the Company's Common Stock on the date of the grant. The fair value is then amortized to compensation expense over the requisite service period or vesting term. During t he six month period ended June 30, 2020, the Company granted 708,916 RSUs to certain employees in exchange for options to purchase 1,417,832 shares of Common Stock held by such employees. On May 8, 2020, 88,695 RSUs vested with the remainder of such RSUs vesting quarterly over a period of two years. Also, during the six months ended June 30, 2020, the Company agreed to grant 1,733,500 RSUs to certain officers and members of the Company’s Board of Directors in exchange for options to purchase 3,467,000 shares of Common Stock held by such officers and directors. However, principally due to the lack of authorized but unissued shares of Common Stock to satisfy certain commitments of the Company, and in lieu of pending efforts to restructure certain issued and outstanding preferred stock and secure additional working capital, the Company and certain officers and directors have agreed to suspend the issuance of such RSUs in exchange for their options. . In addition to the aggregate 6,110,332 options exchanged or pending exchange as disclosed above, an additional 959,840 options expired unexercised during the six months ended June 30, 2020. The Company determined that the exchange agreements are a modification of a share-based payment award under ASC 718. Accordingly, the Company computed any incremental compensation expense as a component of the total compensation cost to be measured at the modification date. Aggregate incremental compensation expense measured from the modifications of stock option was approximately $385,000. The intrinsic value of options exercisable and outstanding at June 30, 2020 was $0. T he aggregate intrinsic value for all options outstanding as of June 30, 2020 was approximately $368,000. Stock-based compensation expense for employees, officers and members of the Company’s Board of Directors, related to RSUs, equity options, and the modifications of equity options, has been classified as follows in the accompanying condensed consolidated statements of operations (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Cost of revenue $ 2 $ 4 $ 5 $ 7 General and administrative 89 97 156 190 Sales and marketing 10 42 100 81 Research and development 35 38 61 69 Total $ 136 $ 181 $ 322 $ 347 |